The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
Open accessAbstract
Purpose: There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence. Methods: Eighty-seven patients with chronic-phase CML treated with imatinib 400 mg/d for a median of 59.7 months (range, 25 to 104 months) who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device. Adherence was correlated with levels of molecular response. Other factors that could influence outcome were also analyzed. Results: Median adherence rate was 98% (range, 24% to 104%). Twenty-three patients (26.4%) had adherence ≤ 90%; in 12 of these patients (14%), adherence was ≤ 80%. There was a strong correlation between adherence rate (≤ 90% or > 90%) and the 6-year probability of a 3-log reduction (also known as major molecular response [MMR]) in BCR-ABL1 transcripts (28.4% v 94.5%; P < .001) and also complete molecular response (CMR; 0% v 43.8%; P = .002). Multivariate analysis identified adherence (relative risk [RR], 11.7; P = .001) and expression of the molecular human organic cation transporter-1 (RR, 1.79; P = .038) as the only independent predictors for MMR. Adherence was the only independent predictor for CMR. No molecular responses were observed when adherence was ≤ 80% (P < .001). Patients whose imatinib doses were increased had poor adherence (86.4%). In this latter population, adherence was the only independent predictor for inability to achieve an MMR (RR, 17.66; P = .006). Conclusion: In patients with CML treated with imatinib for some years, poor adherence may be the predominant reason for inability to obtain adequate molecular responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationInterventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationPrognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Self-citationNonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Active transport of imatinib into and out of cells: implications for drug resistance
Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004) · Blood · doi:10.1182/blood-2003-12-4276 · Cited by 643
Larson, R. A., Druker, B. J., Guilhot, F., O'Brien, S. G., Riviere, G. J., Krahnke, T., Gathmann, I., & Wang, Y. (2008) · Blood · doi:10.1182/blood-2007-10-116475 · Cited by 643
Noens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Mineur, P., Van Eygen, K., MacDonald, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196543 · Cited by 616
Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.-A., Lassalle, R., Marit, G., Reiffers, J., Begaud, B., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036012 · Cited by 612
Self-citationAdherence to Therapy With Oral Antineoplastic Agents
Partridge, A. H. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.9.652 · Cited by 584
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569 · cited 1×
“The extent to which patients with cancer comply with prescribed oral anticancer therapy ranges between 16% and 100%, depending on the specific therapy and method used to measure adherence.(10) The methods used to monitor drug adherence include self reporting, frequency of repeat prescriptions, pill counts, drug plasma…”
Methodde Lavallade, H., Apperley, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8154 · Cited by 551
Self-citationRousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M., Maarek, O., Blanchet, O., Marit, G., Gluckman, E., Reiffers, J., et al. (2007) · Blood · doi:10.1182/blood-2006-03-011239 · Cited by 538
Self-citationWhite, D. L., Saunders, V. A., Dang, P., Engler, J., Zannettino, A. C. W., Cambareri, A. C., Quinn, S. R., Manley, P. W., & Hughes, T. P. (2006) · Blood · doi:10.1182/blood-2005-11-4687 · Cited by 435
Compliance Declines Between Clinic Visits
Cramer, J. A. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.7.1509 · Cited by 405
Canellos, G. P. (1976) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)31845-4 · Cited by 343
White, D. L., Saunders, V. A., Dang, P., Engler, J., Venables, A., Zrim, S., Zannettino, A., Lynch, K., Manley, P. W., & Hughes, T. (2007) · Blood · doi:10.1182/blood-2007-06-093617 · Cited by 331
Marin, D., Milojkovic, D., Olavarria, E., Khorashad, J. S., de Lavallade, H., Reid, A. G., Foroni, L., Rezvani, K., Bua, M., Dazzi, F., et al. (2008) · Blood · doi:10.1182/blood-2008-06-162388 · Cited by 328
Self-citationWaterhouse, D. M., Calzone, K. A., Mele, C., & Brenner, D. E. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.6.1189 · Cited by 313
Wang, L., Giannoudis, A., Lane, S., Williamson, P. R., Pirmohamed, M., & Clark, R. E. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100268 · Cited by 277
Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
Dulucq, S., Bouchet, S., Turcq, B., Lippert, E., Etienne, G., Reiffers, J., Molimard, M., Krajinovic, M., & Mahon, F.-X. (2008) · Blood · doi:10.1182/blood-2008-03-147744 · Cited by 236
Self-citationStone, V. E. (2001) · Clinical Infectious Diseases · doi:10.1086/322698 · Cited by 216
Patient-centred advice is effective in improving adherence to medicines
Clifford, S., Barber, N., Elliott, R., Hartley, E., & Horne, R. (2006) · Pharmacy World and Science · doi:10.1007/s11096-006-9026-6 · Cited by 198
Khorashad, J. S., de Lavallade, H., Apperley, J. F., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9953 · Cited by 183
Self-citationBranford, S., Rudzki, Z., Harper, A., Grigg, A., Taylor, K. F., Durrant, S., Arthur, C., Browett, P., Schwarer, A. P., David, D. F., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403158 · Cited by 154
Khorashad, J. S., Anand, M., Marin, D., Saunders, S., Al-Jabary, T., Iqbal, A., Margerison, S., Melo, J. V., Goldman, J. M., Apperley, J. F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404137 · Cited by 149
Self-citationKaeda, J., O’Shea, D., Szydlo, R., Olavarría, E., Dazzi, F., Marin, D., Saunders, S. E., Khorashad, J. S., Cross, N. C. P., Goldman, J. M., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3320 · Cited by 122
Self-citationLin, F., Chase, A., Bungey, J., Goldman, J. M., & Cross, N. C. P. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870130207 · Cited by 21
Self-citation
Cited by
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Self-report measures of medication adherence behavior: recommendations on optimal use
Stirratt, M. J., Dunbar-Jacob, J., Crane, H. M., Simoni, J. M., Czajkowski, S., Hilliard, M. E., Aikens, J. E., Hunter, C. M., Velligan, D. I., Huntley, K., et al. (2015) · Translational Behavioral Medicine · doi:10.1007/s13142-015-0315-2 · Cited by 824
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Metadata
- Authors
- Marin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., Paliompeis, C., Latham, V., Foroni, L., Molimard, M., Reid, A., Rezvani, K., de Lavallade, H., Guallar, C., Goldman, J., & Khorashad, J. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-05-10
- Volume
- 28
- Issue
- 14
- Pages
- 2381-2388
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166270808
- Cited by
- 909
- References
- 32
- FWCI
- 43.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.